Desmoid Tumor clinical trials at UCSF
3 in progress, 2 open to eligible people
A desmoid tumor is a growth in your connective tissue that can be very aggressive. UCSF is studying tegavivint to find the safest dose for treating desmoid tumors. UCSF is also gathering health information from young patients with cancer to improve understanding of these conditions.
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
open to eligible people ages 12 months to 30 years
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interferes with the binding of beta-catenin to TBL1, which may help stop the growth of tumor cells by blocking the signals passed from one molecule to another inside a cell that tell a cell to grow.
San Francisco, California and other locations
Project: Every Child for Younger Patients With Cancer
open to eligible people ages up to 25 years
This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.
Oakland, California and other locations
New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery
Sorry, in progress, not accepting new patients
This phase II trial studies the side effects and how well nirogacestat works in treating patients less than 18 years of age with desmoid tumors that has grown after at least one form of treatment by mouth or in the vein that cannot be removed by surgery. Nirogacestat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Oakland, California and other locations
Our lead scientists for Desmoid Tumor research studies include Arun A. Rangaswami Kieuhoa T. Vo.
Last updated: